Adaptimmune Therapeutics (STU:473A) YoY EBITDA Growth : 10.47% (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Adaptimmune Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was 10.47%.

Adaptimmune Therapeutics's EBITDA per Share for the three months ended in Mar. 2025 was €-0.15.

Adaptimmune Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Adaptimmune Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptimmune Therapeutics YoY EBITDA Growth Chart

Adaptimmune Therapeutics Annual Data

Trend

Jun15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

35.75

-21.76

-3.96

49.08

57.48

Adaptimmune Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
YoY EBITDA Growth	Get a 7-Day Free Trial															-693.10	384.78	74.14	-38.04	10.47

Adaptimmune Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Adaptimmune Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(-0.199	-	-0.468)	/	\| -0.468 \|
=	57.48 %

Adaptimmune Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2025 )
=	(EBITDA per Share (Q: Mar. 2025 )	-	EBITDA per Share (Q: Mar. 2024 ))	/	\| EBITDA per Share (Q: Mar. 2024 )) \|
=	(-0.154	-	-0.172)	/	\| -0.172 \|
=	10.47 %

Adaptimmune Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptimmune Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (STU:473A) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

ADAP:USA 473A:Germany

Address

60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.adaptimmune.com

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Adaptimmune Therapeutics Headlines

No Headlines